Shots:
- Summit has entered into a clinical trial collaboration with Pfizer to assess safety & anti-tumor activity of ivonescimab with multiple Pfizer’s vedotin ADCs in solid tumors; trials are expected to initiate in mid-2025
- As per the deal, Summit will supply ivonescimab for proposed trials & Pfizer will handle operations, with both firms jointly overseeing the trials. Each party retains rights to their respective products
- Ivonescimab (bsAb) is being evaluated in 3 P-III trials: HARMONi (with CT vs PBO + CT) for EGFRm LA/M non-sq. NSCLC with topline data expected in mid-2025, HARMONi-3 (with CT vs Keytruda + CT) for 1L metastatic NSCLC & HARMONi-7 (vs Keytruda) for 1L, PD-L1+ metastatic NSCLC
Ref: Bussinesswire | Image: Pfizer & Summit Pharmaceuticals
Related News:- Pfizer Reports Data from P-III (TALAPRO-2) Trial of Talzenna + Xtandi for Metastatic Castration Resistant Prostate Cancer (mCRPC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
